Although tremendous research has reported the protective effects of natural compounds in nonalcoholic fatty liver disease (NAFLD), there is still no approved drug. This study aimed to examine the efficacy of in NAFLD in preclinical studies. A total of 41 studies were identified by searching the PubMed, Web of Science, and Cochrane Library databases. The methodological quality was assessed by the risk of bias tool from the Systematic Review Center for Laboratory Animal Experimentation. The standardized mean difference (SMD) with a 95% confidence interval was calculated, and the random effects model was used to examine overall efficacy or heterogeneity. The publication bias was analyzed by Egger's test. The results showed that treatment significantly reduced the systemic levels of alanine aminotransferase (SMD: -2.15 IU/L; < 0.0001), aspartate aminotransferase (SMD: -2.86 IU/L; < 0.0001), triglyceride (SMD: -2.86 mg/dL; < 0.0001), total cholesterol (SMD: -1.69 mg/dL; < 0.0001), low-density lipoprotein (SMD: -1.46 mg/dL; < 0.0001), and fasting glucose (SMD: -1.45 mg/dL; < 0.0001) while increasing high-density lipoprotein (SMD: 1.22 mg/dL; = 0.0002) in NAFLD regardless of animal models or species. These findings may suggest that is a promising therapeutic agent for NAFLD treatment.